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York, New YorkObjective: To determine whether performing comprehensive chromosome screening (CCS) and transferring a single euploid blastocyst
can result in an ongoing pregnancy rate that is equivalent to transferring two untested blastocysts while reducing the risk of multiple
gestation.
Design: Randomized, noninferiority trial.
Setting: Academic center for reproductive medicine.
Patient(s): Infertile couples (n¼ 205) with a female partner less than 43 years old having a serum anti-M€ullerian hormone levelR1.2
ng/mL and day 3 FSH <12 IU/L.
Intervention(s): Randomization occurred when at least two blastocysts were suitable for trophectoderm biopsy. The study group (n ¼
89) had all viable blastocysts biopsied for real-time, polymerase chain reaction–based CCS and single euploid blastocyst transfer. The
control group (n ¼ 86) had their two best-quality, untested blastocysts transferred.
Main Outcome Measure(s): The ongoing pregnancy rate toR24 weeks (primary outcome) and the multiple gestation rate.
Result(s): The ongoing pregnancy rate per randomized patient after the ﬁrst ET was similar between groups (60.7% after single euploid
blastocyst transfer vs. 65.1% after untested two-blastocyst transfer; relative risk [RR], 0.9; 95% conﬁdence interval [CI], 0.7–1.2). A
difference of greater than 20% in favor of two-blastocyst transfer was excluded. The risk of multiple gestation was reduced after
single euploid blastocyst transfer (53.4% to 0%), and patients were nearly twice as likely to have an ongoing singleton pregnancy
(60.7% vs. 33.7%; RR, 1.8; 95% CI, 1.3–2.5).
Conclusion(s): In women%42 years old, transferring a single euploid blastocyst results in ongoing pregnancy rates that are the sameUse your smartphoneas transferring two untested blastocysts while dramatically reducing the risk of twins.
Clinical Trial Registration Number: NCT01408433. (Fertil Steril 2013;100:100–7. 2013 by
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Open access under CC BY-NC-ND license.I nfertile couples undergoing an IVFcycle face enormous emotional,physical, and ﬁnancial burdens. In
most cases they have struggled with in-
fertility for more than a year and failed
to conceive with lesser means. Since the
majority of IVF cycles in the United
States are uninsured, patients have an
incentive to maximize their chance of
delivery in a given cycle to reduce the
ﬁnancial burden they must shoulder
(1). When seeking care, patients often
compare clinics based on their reported
delivery rates per cycle. TheseVOL. 100 NO. 1 / JULY 2013
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clinicians to transfer multiple embryos, increasing the risk
of twin and higher order pregnancies, which are at higher
risk of maternal and neonatal complications than singleton
pregnancies (2, 3). The societal cost of caring for preterm
neonates resulting from multiple pregnancies far outweighs
the couple's savings from preventing failed cycles (4, 5).
Thus, as currently practiced, the infertile couple often
chooses a transfer strategy that minimizes its own ﬁnancial
burden while assuming increased medical risk and adding
to overall health care costs.
Multiple gestations is almost entirely preventable with the
transfer of a single embryo after each IVF cycle. However, de-
spite recommendations to consider elective single ET (eSET) for
young, good-prognosis patients (6, 7), this technique is used in
only 4% of cycles and 47% of all babies born as a result of IVF
performed in the United States are part of a multiple birth (8).
The reluctance to accept eSET likely stems from the dimin-
ished chance for a delivery when only a single embryo is trans-
ferred (9, 10), reﬂecting the inadequacy of current methods of
embryo selection. Embryonic aneuploidy (chromosomal
imbalance) is the leading cause of implantation failure and
miscarriage after IVF and increases dramatically with
increasing maternal age (11–13). With eSET, the entire cycle
outcome is dependent on the fate of the selected embryo; if
an aneuploid embryo is selected, there is essentially no
chance for delivery of a healthy newborn.
As currently practiced, the embryo chosen for transfer is se-
lected based on temporal and morphologic grading criteria re-
lated to its appearance under the microscope. Embryo grading
has signiﬁcant inter- and intraobserver variability and has not
been shown to correlate with chromosomal status (14–16).
Extending embryo culture to the blastocyst stage was shown to
improve outcomes from eSET (17), but morphologically normal
blastocysts retain a signiﬁcant risk of aneuploidy (18, 19).
Another selection strategywould be to culture all embryos
to the blastocyst stage, perform a trophectoderm biopsy, use
an assay to rapidly analyze the copy number status of each
chromosome, and then transfer a single euploid blastocyst
(20). This strategy was shown to improve singleton delivery
rates in a retrospective study (18) and a small prospective
study in young, good-prognosis patients (21).
The goal of the current trial was to determine whether in-
fertile couples would have as good a chance for an ongoing
pregnancy after transfer of a single euploid blastocyst as
they would with the transfer of two untested blastocysts. In
addition, we hypothesized they would have a signiﬁcantly re-
duced risk of twins after single euploid blastocyst transfer. Al-
though previous studies have shown similar delivery rates
when two separate single ETs are performed (22, 23), the
ability to achieve equivalent outcomes with one transfer has
the potential to make single ET a more acceptable option
regardless of the patient's age (24).MATERIALS AND METHODS
Patient Population
The Blastocyst Euploid Selective Transfer (BEST) Trial was
offered to women with an indication for IVF who were%42VOL. 100 NO. 1 / JULY 2013years old at the start of their IVF cycle. They were eligible
to participate if they had at most one prior failed IVF cycle,
a normal endometrial cavity, and normal ovarian reserve as
determined by a serum anti-M€ullerian hormone level of
R1.2 ng/mL and a day 3 FSH level of <12 IU/L. Couples
with severe male factor infertility requiring surgical
sperm extraction were excluded as were women with
anovulatory polycystic ovarian syndrome or a body mass
index >30 kg/m2. To be eligible for randomization, there
had to be at least two expanded blastocysts suitable for
transfer or cryopreservation by day 6 of embryo development.Study Design
The protocol was approved by the Copernicus Group Indepen-
dent Review Board (Durham, NC) and registered with clinical-
trials.gov (NCT01408433) before patient enrollment. All
embryology procedures were performed at Reproductive
Medicine Associates of New Jersey, and patients gave consent
between August 2011 and June 2012.
The IVF cycle was performed per practice routine. Multi-
follicular ovarian stimulation was achieved with highly puri-
ﬁed urinary gonadotropins: urofollitropin (Bravelle, Ferring
Pharmaceuticals) and menotropins (Menopur, Ferring Phar-
maceuticals). Final oocyte maturation was induced with
5,000 to 10,000 IU of hCG when at least two follicles reached
18 mm in maximal diameter. Patients determined to be at risk
for ovarian hyperstimulation syndrome by their physician re-
ceived 5,000 IU of hCG. Transvaginal oocyte retrieval was per-
formed 36 hours after hCG administration. Fertilization was
achieved with intracytoplasmic sperm injection in all cases
owing to the possibility of preimplantation genetic testing.
Normally fertilized zygotes were cultured in cleavage media
in a low-oxygen tension environment. On day 3 of embryo de-
velopment, all cleaved embryos underwent laser-assisted
hatching of the zona pellucida to facilitate possible trophecto-
derm biopsy. All embryos were then placed in extended cul-
ture media regardless of the size or quality of the cohort.
Randomization occurred when at least two embryos had
developed sufﬁciently to allow for blastocyst-stage biopsy.
A random number function was used to create blocks of 10
with patients assigned to the two groups in a 1:1 allocation.
In the study group, all viable blastocysts would undergo tro-
phectoderm biopsy with rapid, real-time polymerase chain re-
action (PCR) based comprehensive chromosome screening
(CCS) and transfer of the single, best-quality euploid blasto-
cyst. The control group would receive traditional,
morphology-based transfer of two untested blastocysts. The
randomization was stratiﬁed by age group (<35, 35–37,
38–40, 41–42 years) and whether fresh or frozen ET was to
be performed. Allocation concealment was achieved using se-
quentially numbered, opaque, sealed envelopes. The study
was not blinded—patients were informed at the time of trans-
fer or cryopreservation whether they were to receive one or
two blastocysts and the results of chromosome screening if
it had been performed.
Embryos were graded on day 5 according to the Gardner
criteria by assessing degree of expansion and the morphology
of the inner cell mass and trophectoderm (25). Patients were101
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blastocysts (expansion stage R3) by the afternoon of day 5
and they had no contraindications to receiving a transfer.
All fresh transfers were performed in the morning of day 6,
which is standard procedure for the practice.
Patients with fewer than two expanded blastocysts on
day 5 were not eligible for fresh transfer owing to embryo-
endometrial dyssychrony (26–28). Their embryos were
reassessed and they were randomized if there were at least
two expanded blastocysts by the afternoon of day 6. All
viable blastocysts were cryopreserved by vitriﬁcation for
use in a future frozen ET cycle. Patients with only one
expanded blastocyst were not randomized and received
a nonelective single blastocyst transfer in the fresh cycle if
the embryo was expanded on day 5 or in a frozen transfer if
it did not expand until day 6.
Some patients were not eligible for fresh ET owing to risk
of ovarian hyperstimulation syndrome, abnormal endome-
trial proliferation (<7 mm thickness on ultrasound), prema-
ture P elevation (R2 ng/mL before administration of hCG),
or detection of hydrosalpinges that communicated with the
endometrial cavity. These patients were randomized on day
6 to the two previously described groups in the frozen transfer
arm of the study.
For patients randomized to fresh single euploid blastocyst
transfer, all expanded blastocysts underwent laser-assisted
trophectoderm biopsy late in the afternoon of day 5. The bi-
opsy was processed for CCS by placing it in an alkaline lysis
buffer and performing real-time PCR as described elsewhere
(20). A copy number assignment was made for each chromo-
some using a modiﬁcation of the comparative threshold cycle
method (29). A predicted karyotype was assigned to each blas-
tocyst by a certiﬁed cytogeneticist (Supplemental Fig. 1). Em-
bryos with failed ampliﬁcation or results that were
nondiagnostic according to previously established thresholds
were subject to repeat biopsy and analysis. The single, mor-
phologically best euploid blastocyst was selected for
ultrasound-guided transfer on the morning of day 6. All other
euploid blastocysts were vitriﬁed individually. Additional
blastocysts that expanded by the afternoon of day 6 under-
went trophectoderm biopsy and were vitriﬁed.
For patients randomized to the control group, two blasto-
cysts were selected by traditional morphologic grading crite-
ria for transfer on the morning of day 6. All other viable
blastocysts were vitriﬁed in pairs. No embryos underwent tro-
phectoderm biopsy.
In both groups, the luteal phase was supported with 100
mg of P (Endometrin, Ferring Pharmaceuticals) inserted vag-
inally 3 times daily until 8 weeks of gestation.
Patients randomized in the frozen transfer arm were im-
mediately prepared for a synthetic cycle by starting oral E2
supplementation on the third day of their menses. When the
endometrial thickness reached at least 7 mm after at least 1
week of E2 supplementation, IM P was initiated at a dose of
50 mg daily. Frozen ET was performed 5 days after starting
P. Supplemental E2 was continued until 8 weeks of gestation
and P was continued until 10 weeks of gestation.
Pregnancy monitoring was per practice routine with pa-
tients receiving their ﬁrst serum pregnancy test approximately1028 days after ET. If the initial hCG level was R5 IU/L, it was
repeated 48 hours later. Those with normally rising levels had
a transvaginal ultrasound performed 1 week later and weekly
thereafter. Patients were discharged to an obstetrician at 9
weeks of gestation.Calculation of Sample Size
Given that prior trials demonstrated single ET to be inferior to
double ET, this study was designed as a noninferiority trial
with a margin of 20% assuming a baseline ongoing preg-
nancy rate of 60% in each group. To be 80% certain that
the upper limit of a one-sided 95% conﬁdence interval (CI)
would exclude a difference in favor of the two-blastocyst
transfer control group by more than 20%, 75 patients were re-
quired in each group. Since it was estimated that approxi-
mately 25% of patients would not be randomized owing to
insufﬁcient blastocyst development, 200 cycles were planned.Statistical Analysis
An ongoing pregnancy was a pregnancy that reached a viable
gestational age ofR24 weeks.
A clinical miscarriage was the loss of a pregnancy after
visualization of a gestational sac. The sustained implantation
rate was the number of gestational sacs with fetal cardiac ac-
tivity at the time of discharge to obstetrical care divided by the
number of embryos transferred. A multiple pregnancy had
more than one fetus with cardiac activity at the time of dis-
charge to obstetrical care.
The primary outcome was the rate of ongoing pregnancy
per patient randomized. The outcome of only the ﬁrst transfer
was included. Secondary outcomes included the multiple
pregnancy rate, sustained implantation rate, and clinical mis-
carriage rate.
The ongoing pregnancy rates were compared by calculat-
ing 95% CIs of the relative risk and risk difference using
OpenEpi Version 2.3.1. The rates of multiple pregnancy, im-
plantation, and clinical miscarriage were compared using
a c2 distribution; P< .05 was considered statistically signiﬁ-
cant. A t test or Mann-Whitney U–test was used for demo-
graphic data where appropriate. Comparisons were made
using both intention-to-treat and per-protocol analyses. In
the per-protocol analysis, patients were excluded if they did
not adhere to clinical recommendations for luteal phase sup-
port or had their frozen ET cycle cancelled owing to abnormal
endometrial development. Descriptive statistics are reported
with mean  SD and range.
RESULTS
A total of 205 patient initiated gonadotropin stimulation with
175 randomized and 30 withdrawn before randomization
(Fig. 1). Of the 175 randomized patients, 76 (43.4%) were
<35 years old, 54 (30.9%) were 35–37 years old, 34 (19.4%)
were 38–40 years old, and 11 (6.3%) were 41–42 years old.
Sixty-nine percent of ETs were performed in the fresh cycle.
One patient did not have a fresh transfer owing to nondiag-
nostic CCS results; her blastocysts were rebiopsied and cryo-
preserved. Two patients (both 40 years old) did not haveVOL. 100 NO. 1 / JULY 2013
FIGURE 1
Flow chart showing enrollment and status of study cycles.
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graphics of the patients in each group were similar (Table 1).Intention-to-Treat Analysis
CCS results. The 89 patients randomized to single euploid
blastocyst transfer had a total of 521 blastocysts of sufﬁcient
quality to biopsy. After the initial biopsy, 2% of embryos did
not yield a diagnostic result. Each embryo was rebiopsied and
a reliable result was obtained. The overall rate of aneuploidy
was 31% (162/521). As expected, there was an association be-
tween increasing aneuploidy and maternal age (r ¼ 0.53,
P< .001). Sixteen aneuploid blastocysts with the ability to re-
sult in viable pregnancies (four trisomy 13; ﬁve trisomy 18;
six trisomy 21; one 45,X; one 47,XXY; and one 47,XYY)
were detected and excluded from transfer, perhaps preventing
anomalous pregnancies.
Clinical outcomes. The clinical performance in the IVF cycle
was similar between groups (Table 2; Fig. 2). The ongoing
pregnancy rate after each patient's ﬁrst transfer, whether
fresh or frozen, was 60.7% (54/89) after single euploid blasto-
cyst transfer and 65.1% (56/86) after untested two-blastocystVOL. 100 NO. 1 / JULY 2013transfer. The 95% CI of the difference in ongoing pregnancy
rate was18.7% to 9.9%, indicating that single euploid blas-
tocyst transfer is not inferior to two-blastocyst transfer. The
ongoing pregnancy rates after single euploid blastocyst trans-
fer and untested two-blastocyst transfer were similar in fresh
transfers (63.9% [39/61] vs. 70.5% [43/61]; P¼ .4) and frozen
transfers (53.6% [15/28] vs. 52.0% [13/25]; P¼ .9).
The multiple pregnancy rate at the time of discharge to
obstetrical care was signiﬁcantly higher in the two-
blastocyst transfer group, (53.4% [31/58] to 0% [0/57];
P< .001). Two patients with twin pregnancies delivered at
a nonviable gestational age. One patient in the two-
blastocyst transfer group had a preterm triplet delivery owing
to monozygotic twinning of one embryo. There were no
monozygotic twins after single euploid blastocyst transfer.
Importantly, patients who received single euploid blasto-
cyst transfer were nearly twice as likely to have an ongoing
singleton pregnancy as those with two-blastocyst transfer
(60.7% [54/89] vs. 33.7% [29/86]; relative risk, 1.8; 95% CI,
1.3–2.5; P< .001).
There was a trend toward a higher sustained implantation
rate after single euploid blastocyst transfer (63.2% [55/87] vs.103
TABLE 1
Characteristics of the patients.
Characteristic
Single euploid blastocyst
transfer (n[ 89)
Double blastocyst
transfer (n[ 86) P value
Age at oocyte retrieval, y
Mean  SD 35.1  3.9 34.5  4.7 .5
Range 25.1–41.4 22.9–42.6
Body mass index, kg/m2
Mean  SD 23.5  3.5 23.8  3.2 .4
Range 17.6–30.2 18.0–30.8
Anti-M€ullerian hormone level, ng/mL
Mean  SD 3.5  2.4 4.0  3.5 .2
Range 1.2–18.0 1.2–22.0
Day 3 FSH, IU/L
Mean  SD 6.9  1.8 6.6  1.7 .2
Range 3.2–11.6 2.8–10.8
Primary cause of infertility, n (%)
Male factor 25 (28.1) 22 (25.6) .9
Unexplained 24 (27.0) 24 (27.9)
Ovulatory dysfunction 12 (13.5) 17 (19.8)
Tubal factor 11 (12.4) 13 (15.1)
Endometriosis 6 (6.7) 4 (4.7)
Other 11 (12.4) 6 (7.0)
History of previous pregnancies, n (%) 47 (52.8) 42 (48.8) .6
Live birth 23 (25.8) 22 (25.6)
Clinical miscarriage 25 (28.1) 14 (16.3)
Termination of pregnancy 11 (12.4) 9 (10.5)
History of prior treatment with IVF, n (%) 18 (20.2) 16 (18.6) .8
Live birth 8 (9.0) 4 (4.7)
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are not routinely offered eSET, the sustained implantation
rate was higher in the single euploid blastocyst transfer groupTABLE 2
Outcomes according to treatment group (intention-to-treat analysis).
Outcome
Single e
tran
Total dose of gonadotropins, ampules
Mean  SD 3
Range
E2, pg/mL, at surge
Mean  SD 2,4
Range 5
Retrieved oocytes
Mean  SD 1
Range
Fertilized oocytes (two pronuclei)
Mean  SD 1
Range
High-quality blastocysts
Mean  SD
Range
Vitriﬁed blastocysts
Mean  SD
Range
Vitriﬁed euploid blastocysts
Mean  SD
Range
Patients who received fresh ET (%)
Patients who received frozen embryo transfer due to
Embryo-endometrial dyssynchrony
Ovarian hyperstimulation syndrome risk
Hydrosalpinx
Nondiagnostic result of embryo biopsy
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104(58.3% [28/48] vs. 39.8% [39/98]; P¼ .03). This improvement
in the implantation rate likely relates to the higher probability
of the CCS result overriding traditional embryo morphologyuploid blastocyst
sfer (n[ 89)
Double blastocyst
transfer (n[ 86) P value
7.8  12.9 37.0  13.6 .7
15.5–72 14.5–81
37  1,212 2,540  1,236 .6
13–6,267 605–6,000
6.9  8.4 15.7  7.1 .6
5–45 3–42
1.1  5.9 10.8  5.7 .9
4–30 3–33
5.8  3.6 5.3  3.0 .5
2–22 2–18
3.7  2.9 3.9  2.8 .5
0–17 0–16
3.2  2.8 NA
0–17 NA
60 (67) 61 (71) .6
22 20
5 3
0 2
1 0
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FIGURE 2
Equivalent ongoing pregnancy rates with signiﬁcantly fewer multiples after single euploid blastocyst transfer. (A) In the intention-to-treat analysis,
the ongoing pregnancy rate (R24 weeks gestation) after single euploid blastocyst transfer was not inferior to the rate after transferring two
untested blastocysts. (B) In the single euploid blastocyst transfer group, all ongoing pregnancies were singletons. After accounting for second
trimester losses and vanishing twins, multiples accounted for 48% of the ongoing pregnancies after untested two-blastocyst transfer.
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gle euploid blastocyst transfer, but the difference was not sig-
niﬁcant (11.5% [7/61] vs. 20.0% [14/70]; P¼ .2).
Although patients in the single euploid blastocyst transfer
group had aneuploid blastocysts discarded, they also had
fewer embryos transferred. The overall effect resulted in an
equivalent number of supernumerary vitriﬁed blastocysts in
each group after their ﬁrst transfer (P¼ .3); however, patients
in the study group had the added assurance that their vitriﬁed
blastocysts were all euploid. After their ﬁrst single euploid
blastocyst transfer, 81% of patients had at least one additional
euploid blastocyst cryopreserved for possible future transfer.Per-Protocol Analysis
Among patients who followed the study protocol (85 in each
group), the ongoing pregnancy rate was 63.5% (54/85) after
single euploid blastocyst transfer and 64.7% (55/85) afterVOL. 100 NO. 1 / JULY 2013two-blastocyst transfer. The 95% CI of the difference in ongo-
ing pregnancy rates was 14.8% to þ14.1%. The sustained
implantation rate was signiﬁcantly higher in the single eu-
ploid blastocyst transfer group (66.3% [55/83] vs. 51.2%
[87/170]; P¼ .02).DISCUSSION
The BEST Trial has demonstrated that altering embryo selec-
tion by choosing a single, chromosomally normal blastocyst
for transfer results in ongoing pregnancy rates that are not in-
ferior to those attained when transferring two blastocysts
with an unknown chromosomal complement. Given the re-
duction in the proportion of multiple pregnancies, the long-
term outcomes from this treatment paradigm are likely to
be safer, resulting in fewer maternal and neonatal complica-
tions. Twins have a signiﬁcantly higher risk of costly neonatal
intensive care unit stays, resulting in estimates that twin105
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(30). By reducing the risk of preterm deliveries, the BEST
treatment strategy is likely to be cost effective, even
accounting for the additional cost of embryo biopsy and
CCS. Importantly, while single ET has been promoted for
good-prognosis patients, even patientsR40 years old are at
a signiﬁcantly increased risk of multiple birth when more
than one embryo is transferred (31). The current trial demon-
strates that it is feasible to consider women up to age 43 for
single ET, provided they can produce a euploid blastocyst.
The concept of embryo selection has recently been criti-
cized in favor of sequentially transferring individual un-
screened, vitriﬁed embryos (32). However, the results of the
BEST Trial show that by enhancing embryo selection for the
ﬁrst transfer, excellent ongoing pregnancy rates can be
achieved across age groups, while nearly eliminating the
risk of multiple gestation. A prior retrospective study showed
that fewer patients had clinical miscarriages requiring
surgical intervention after single euploid blastocyst transfer
(18). The ability to prevent aneuploid pregnancies allows
many patients to avoid the physical and emotional burden
of miscarriage and is arguably a more patient-friendly ap-
proach. Consistent with prior studies, aneuploidy is not the
sole cause of miscarriage, and this selection strategy cannot
completely eliminate miscarriages.
Although there is concern that a strategy of blastocyst
culture may result in higher cycle cancellation rates (33),
the current study demonstrates that, using even a modest
ovarian reserve requirement, only 5.4% percent of patients
did not produce a transferable blastocyst. Furthermore,
86.2% of patients had at least two blastocysts and were ran-
domized, including 76.3% (45/59) who were R38 years old.
Only two patients were cancelled due to aneuploidy screen-
ing. Although young patients with diminished ovarian re-
serve were not included, they too are likely to beneﬁt from
a reduced risk of multiple gestation should they produce
two euploid blastocysts in a given cycle.
Earlier attempts to improve IVF outcomes with aneu-
ploidy screening did not show beneﬁt in prospective trials
(34). Those studies were conducted using ﬂuorescence in
situ hybridization (FISH), a technology whose accuracy was
not properly validated in embryos. Research using more ro-
bust technologies such as single nucleotide polymorphism
microarrays demonstrated that FISH overdiagnoses aneu-
ploidy in some embryos and underdiagnoses aneuploidy for
chromosomes that are not probed (35, 36). The stage of
embryo biopsy may have also hampered prior attempts to
apply aneuploidy screening clinically. Recent evidence
suggests that blastocyst-stage trophectoderm biopsy, which
involves removal of extraembryonic cells destined to form
the placenta and membranes, may be safer and more accurate
than cleavage-stage blastomere biopsy (37, 38). The screening
technology used in this trial underwent extensive validation
to document its accuracy in preclinical trials (20) and to
demonstrate that embryos diagnosed as aneuploid possess
negligible reproductive potential (11).
Many infertile couples initially report a desire to have
twins (39). At ﬁrst glance, this is understandable given their
long struggle with childlessness. However, multiple gestation106has inherent risks that all patients want to avoid, including
preeclampsia, obstetrical hemorrhage, neonatal intensive
care unit stays, and increased neonatal and maternal mortal-
ity. The obstetrical complications often lead to recommended
bed rest and lost time from work, and there may be an in-
creased risk of divorce among parents of twins (40). After re-
ceiving proper counseling about the risks of twins, many
patients prefer singleton over twin pregnancies (39).
A recent meta-analysis showed that slightly more single-
tons were born after double ET (29.5%) than after single ET
(25.9%) when the same selection criteria were used in both
groups (9). To increase the number of singleton deliveries,
which are considered the ideal outcome of IVF (41), an en-
hanced method of embryo selection that results in higher im-
plantation rates is required. The results of the BEST Trial
demonstrate that with a validated method for assessing the
chromosomal status of blastocysts, singleton delivery rates
can be improved without compromising overall success rates.
This treatment paradigm has the potential to improve the ef-
ﬁcacy and safety of assisted reproductive technologies with
resulting cost savings by preventing twins and higher order
multiples. In so doing, the infertile couple's interest in maxi-
mizing success rates and minimizing the burden of treatment
would dovetail with the need to improve safety and minimize
overall health care costs.
Acknowledgments: All medications used in this trial were
provided with the assistance of a grant from Ferring Pharma-
ceuticals. Ferring had no role in the design of the study, data
collection, or preparation of the manuscript. The authors
would like to acknowledge Monica Benson, Stephanie Sgam-
bati, and the Clinical Research Team at Reproductive Medi-
cine Associates of New Jersey for recruiting patients and
coordinating their cycles. The authors also acknowledge
Heather Garnsey and the team of RMA Genetics for coordi-
nating CCS data.
REFERENCES
1. Stillman RJ, Richter KS, Banks NK, Graham JR. Elective single embryo trans-
fer: a 6-year progressive implementation of 784 single blastocyst transfers
and the inﬂuence of payment method on patient choice. Fertil Steril 2009;
92:1895–906.
2. American College of Obstetricians and Gynecologists Committee on Prac-
tice Bulletins-Obstetrics. ACOG Practice Bulletin #56: Multiple gestation:
complicated twin, triplet, and high-order multifetal pregnancy. Obstet Gy-
necol 2004;104:869–83.
3. Reddy UM, Wapner RJ, Rebar RW, Tasca RJ. Infertility, assisted reproductive
technology, and adverse pregnancy outcomes: executive summary of a Na-
tional Institute of Child Health and Human Development workshop. Obstet
Gynecol 2007;109:967–77.
4. Callahan TL, Hall JE, Ettner SL, Christiansen CL, Greene MF, Crowley WF Jr.
The economic impact of multiple-gestation pregnancies and the contribu-
tion of assisted-reproduction techniques to their incidence. N Engl J Med
1994;331:244–9.
5. Collins J. Cost efﬁciency of reducing multiple births. Reproductive biomed-
icine online 2007;15(Suppl 3):35–9.
6. Practice Committee of the Society for Assisted Reproductive Technology and
Practice Committee of the American Society for Reproductive Medicine.
Guidelines on number of embryos transferred. Fertil Steril 2009;92:1518–9.
7. Practice Committee of Society for Assisted Reproductive Technology and
Practice Committee of American Society for Reproductive Medicine. Elective
single-embryo transfer. Fertil Steril 2012;97:835–42.VOL. 100 NO. 1 / JULY 2013
Fertility and Sterility®8. Sunderam S, Kissin DM, Flowers L, Anderson JE, Folger SG, Jamieson DJ,
et al. Assisted reproductive technology surveillance—United States, 2009.
MMWR Surveill Summ 2012;61:1–23.
9. Pandian Z, Bhattacharya S, Ozturk O, Serour G, Templeton A. Number of
embryos for transfer following in-vitro fertilisation or intra-cytoplasmic
sperm injection. Cochrane database of systematic reviews (Online) 2009;
2:CD003416.
10. Gelbaya TA, Tsoumpou I, Nardo LG. The likelihood of live birth and multiple
birth after single versus double embryo transfer at the cleavage stage: a sys-
tematic review and meta-analysis. Fertil Steril 2010;94:936–45.
11. Scott RT Jr, Ferry K, Su J, Tao X, Scott K, Treff NR. Comprehensive chromo-
some screening is highly predictive of the reproductive potential of human
embryos: a prospective, blinded, nonselection study. Fertil Steril 2012;97:
870–5.
12. Nasseri A, Mukherjee T, Grifo JA, Noyes N, Krey L, Copperman AB. Elevated
day 3 serum follicle stimulating hormone and/or estradiol may predict fetal
aneuploidy. Fertil Steril 1999;71:715–8.
13. Werner M, Reh A, Grifo J, Perle MA. Characteristics of chromosomal abnor-
malities diagnosed after spontaneous abortions in an infertile population. J
Assist Reprod Genet 2012;29:817–20.
14. Baxter Bendus AE, Mayer JF, Shipley SK, Catherino WH. Interobserver and
intraobserver variation in day 3 embryo grading. Fertil Steril 2006;86:
1608–15.
15. Paternot G, Devroe J, Debrock S, D'Hooghe TM, Spiessens C. Intra- and
inter-observer analysis in the morphological assessment of early-stage em-
bryos. Reprod Biol Endocrinol 2009;7:105.
16. Paternot G, Wetzels AM, Thonon F, Vansteenbrugge A, Willemen D,
Devroe J, et al. Intra- and interobserver analysis in the morphological assess-
ment of early stage embryos during an IVF procedure: a multicentre study.
Reprod Biol Endocrinol 2011;9:127.
17. Papanikolaou EG, Camus M, Kolibianakis EM, Van Landuyt L, Van
Steirteghem A, Devroey P. In vitro fertilization with single blastocyst-stage
versus single cleavage-stage embryos. N Engl J Med 2006;354:1139–46.
18. Forman EJ, Tao X, Ferry KM, Taylor D, Treff NR, Scott RT Jr. Single embryo
transfer with comprehensive chromosome screening results in improved on-
going pregnancy rates and decreased miscarriage rates. Hum Reprod 2012;
27:1217–22.
19. Fragouli E, Wells D. Aneuploidy in the human blastocyst. Cytogenet Ge-
nome Res 2011;133:149–59.
20. Treff NR, Tao X, Ferry KM, Su J, Taylor D, Scott RT Jr. Development and val-
idation of an accurate quantitative real-time polymerase chain reaction-
based assay for human blastocyst comprehensive chromosomal aneuploidy
screening. Fertil Steril 2012;97:819–24.
21. Yang Z, Liu J, Collins GS, Salem SA, Liu X, Lyle SS, et al. Selection of single
blastocysts for fresh transfer via standard morphology assessment alone
and with array CGH for good prognosis IVF patients: results from a random-
ized pilot study. Mol Cytogenet 2012;5:24.
22. Thurin A, Hausken J, Hillensjo T, Jablonowska B, Pinborg A, Strandell A, et al.
Elective single-embryo transfer versus double-embryo transfer in in vitro fer-
tilization. N Engl J Med 2004;351:2392–402.
23. Lukassen HG, Braat DD, Wetzels AM, Zielhuis GA, Adang EM, Scheenjes E,
et al. Two cycles with single embryo transfer versus one cycle with double
embryo transfer: a randomized controlled trial. Hum Reprod 2005;20:
702–8.VOL. 100 NO. 1 / JULY 201324. Murray S, Shetty A, Rattray A, Taylor V, Bhattacharya S. A randomized com-
parison of alternative methods of information provision on the acceptability
of elective single embryo transfer. Hum Reprod 2004;19:911–6.
25. Gardner DK, Schoolcraft WB. In vitro culture of human blastocysts. In:
Jansen R, Mortimer D, editors. Towards reproductive certainty: infertility
and genetics beyond. Carnforth: Parthenon Press; 1999:378–88.
26. Shapiro BS, Richter KS, Harris DC, Daneshmand ST. A comparison of day 5
and day 6 blastocyst transfers. Fertil Steril 2001;75:1126–30.
27. Barrenetxea G, Lopez de Larruzea A, Ganzabal T, Jimenez R, Carbonero K,
Mandiola M. Blastocyst culture after repeated failure of cleavage-stage em-
bryo transfers: a comparison of day 5 and day 6 transfers. Fertil Steril 2005;
83:49–53.
28. Richter KS, Shipley SK, McVearry I, Tucker MJ, Widra EA. Cryopreserved em-
bryo transfers suggest that endometrial receptivity may contribute to re-
duced success rates of later developing embryos. Fertil Steril 2006;86:
862–6.
29. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
CT method. NatProtocols 2008;3:1101–8.
30. Lukassen HG, Schonbeck Y, Adang EM, Braat DD, Zielhuis GA, Kremer JA.
Cost analysis of singleton versus twin pregnancies after in vitro fertilization.
Fertil Steril 2004;81:1240–6.
31. Lawlor DA, Nelson SM. Effect of age on decisions about the numbers of em-
bryos to transfer in assisted conception: a prospective study. Lancet 2012;
379:521–7.
32. Mastenbroek S, van der Veen F, Aﬂatoonian A, Shapiro B, Bossuyt P,
Repping S. Embryo selection in IVF. Hum Reprod 2011;26:964–6.
33. Glujovsky D, Blake D, Farquhar C, Bardach A. Cleavage stage versus blasto-
cyst stage embryo transfer in assisted reproductive technology. Cochrane
database of systematic reviews (Online) 2012;7:CD002118.
34. Fritz MA. Perspectives on the efﬁcacy and indications for preimplantation
genetic screening: where are we now? Hum Reprod 2008;23:2617–21.
35. Northrop LE, Treff NR, Levy B, Scott RT Jr. SNP microarray-based 24 chromo-
some aneuploidy screening demonstrates that cleavage-stage FISH poorly
predicts aneuploidy in embryos that develop tomorphologically normal blas-
tocysts. Mol Hum Reprod 2010;16:590–600.
36. Treff NR, Levy B, Su J, Northrop LE, Tao X, Scott RT Jr. SNP microarray-based
24 chromosome aneuploidy screening is signiﬁcantly more consistent than
FISH. Mol Hum Reprod 2010;16:583–9.
37. McArthur SJ, Leigh D, Marshall JT, de Boer KA, Jansen RP. Pregnancies and
live births after trophectoderm biopsy and preimplantation genetic testing
of human blastocysts. Fertil Steril 2005;84:1628–36.
38. Kokkali G, Traeger-Synodinos J, Vrettou C, Stavrou D, Jones GM, Cram DS,
et al. Blastocyst biopsy versus cleavage stage biopsy and blastocyst transfer
for preimplantation genetic diagnosis of beta-thalassaemia: a pilot study.
Hum Reprod 2007;22:1443–9.
39. Ryan GL, Sparks AE, Sipe CS, Syrop CH, Dokras A, Van Voorhis BJ. A man-
datory single blastocyst transfer policy with educational campaign in
a United States IVF program reduces multiple gestation rates without sacri-
ﬁcing pregnancy rates. Fertil Steril 2007;88:354–60.
40. Jena AB, Goldman DP, Joyce G. Association between the birth of twins and
parental divorce. Obstet Gynecol 2011;117:892–7.
41. Land JA, Evers JL. Risks and complications in assisted reproduction tech-
niques: report of an ESHRE consensus meeting. Hum Reprod 2003;18:
455–7.107
SUPPLEMENTAL FIGURE 1
Single euploid blastocyst transfer after CCS versus transfer of two untested blastocysts. (A) For patients randomized to single euploid blastocyst
transfer, trophectoderm biopsy was performed on day 5 (fresh transfer) or day 6 (frozen transfers) of in vitro development. The biopsy
underwent an alkaline lysis and then preampliﬁcation of assays on each chromosome. The preampliﬁcation product was placed in a 384-well
reaction plate, and real-time polymerase chain reaction was performed in quadruplicate using a Viia 7 System (Applied Biosystems). A heat
map was generated using the cycle threshold method, and a predicted karyotype was assigned to each embryo. The morphologically best
euploid blastocyst was selected for transfer. (B) For patients randomized to receive a transfer of two untested blastocysts, the blastocysts were
selected by traditional morphologic grading criteria. These embryos were not biopsied or genetically screened.
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